Trivikram Rajkhowa

Hardworking and competent professional with extensive knowledge in clinical laboratory operations. Punctual and professional, willing to work various shifts and driven to perform successfully in solitary role or as part of team.

• A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/ refractory acute myeloid leukemia., Keith W Pratz, Jason Kaplan, Moshe Levy, Dale Bixby, Patrick W. Burke, Harry Erba, Trisha M Wise-Draper, Gail J Roboz, Nikolaos Papadantonakis, Trivikram Rajkhowa, Daniela Hernandez, Iwona Dobler, Richard C Gregory, Cheryl Li, Shining Wang, Kate Stumpo, Karuppiah Kannan, Harry Miao and Mark Levis., Hematologica, 2022, 1-32
• The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia., Theodore Karantanos, Patric Teodorescu, Brandy Perkins, Ilias Christodoulou, Christopher Esteb, Ravi Varadhan, Eric Helmenstine, Trivikram Rajkhowa, Bogdan C. Paun, Challice Bonifant, W. Brian Dalton, Lukasz P. Gondek, Alison R. Moliterno, Mark J. Levis, Gabriel Ghiaur, Richard J. Jones., Science Advances, 2022, 8, 1-11
• A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia., Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Benjamin Powell, Chao Zhang, Yan Ma, Maiko Narahara, Daniela Hernandez, Trivikram Rajkhowa, Gideon Bollag, Mark Levis., Haematologica, 2021, 106, 1022-1033
• Midostaurin after allogenic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia., Richard T. Maziarz, Mark Levis, Mrinal M. Patnaik, Bart L. Scott, Sanjay R. Mohan, Abhinav Deol, Scott D. Rowley, Dennis D. H. Kim, Daniela Hernandez, Trivikram Rajkhowa, Kelly Haines, Gaetano Bonifacio, Patrice Rine, Das Purkayastha, Hugo F. Fernandez., Bone Marrow Transplantation, 2021, 56, 1180-1189
• Preclinical studies of gilteritinib, a next generation FLT3 inhibitor., Lauren Y Lee, Daniela Hernandez, Trivikram Rajkhowa, Samuel C Smith, Jayant Ranganathan Raman, Bao Nguyen, Donald Small, Mark Levis., Blood, 2017, 129, 257-260
• The Combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells., E. Chang, S. Ganguly, T. Rajkhowa, C.D. Gocke, M. Levis and H.Konig., Leukemia, 2016, 30, 1025-1032
• Renal proximal tubule Na, K-ATPase is controlled by CREB-regulated transcriptional coactivation as well as salt-inducible kinase 1., Mary Taub, Sudha Garimella, Dongwook Kim, Trivikram Rajkhowa, Facundo Cutuli., Cell Signaling, 2015, 27, 2568-2578
• Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome., Paolo Strati, Hagop Kantarjian, Farhad Ravandi, Aziz Nazha, Gautam Borthakur, Naval Daver, Tapan Kadia, Zeev Estrov, Guillermo Garcia-Manero, Marina Konopleva, Trivikram Rajkhowa, Menda Durand, Michael Andreeff, Mark Levis, Jorge Cortes., American Journal of Hematology, 2015, 90, 276-281
• Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues., M. Goswami, N. Hensel, B.D. Smith, G.T. Prince, L. Qin, H.I. Levitsky, S. Anthony Strickland, M. Jagasia, B.N. Savani, J.W. Fraser, H. Sadrzadeh, T. Rajkhowa, S. Ito, N.A. Jain, M. Battiwala, A.T. Fathi, M.J. Levis, A.J. Barrett, C.S. Hourigan., Leukemia, 2014, 28, 1167-1170
• Crenolanib is a potent inhibitor of Flt3 with activity against resistance – conferring point mutants., Allison Galanis, Hayley Ma, Trivikram Rajkhowa, Abhijit Ramachandran, Donald Small, Jorge Cortes and Mark Levis., Blood, 2013, 123, 94-100
• Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT3 internal tandem duplication mutation., Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald, Michelle A. Rudek, Trivikram Rajkhowa, Mary Ann Richie, Sherry Pierce, Naval Daver, Guillermo Garcia-Manero, Stefan Faderl, Aziz Nazha, Marina Konopleva, Gautam Borthakur, Jan Burger, Tapan Kadia, Sara Dellasala, Michael Andreeff, Jorge Cortes, Hagop Kantarjian and Mark Levis., Blood, 2013, 121, 4655-4662
• Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML., Amy Sexauer, Alexander Perl, Xiaochuan Yang, Michael Borowitz, Christopher Gocke, Trivikram Rajkhowa, Christian Thiede, Mark Frattini, Grant E G.E. Nybakken, Keith Pratz, Judith Karp, Douglas B.D. Smith and Mark Levis., Blood, 2012, 120, 4205-4214
• A potential therapeutic target for FLT3-ITD AML: PIM1 Kinase., Amir T A.T. Fathi, Omotayo Arowojolu, Ian Swinnen, Takashi Sato, Trivikram Rajkhowa, Donald Small, Fredrik Marmsater, John E J.E. Robinson, Stefan David S.D. Gross, Matthew Martinson, Shelley Allen, Nicholas C N.C. Kallan and Mark Levis., Leukemia Research, 2012, 36, 224-231
• Regulation of Renal Proximal Tubule Na, K-ATPase by Prostaglandins., Maryann B. Herman, Trivikram Rajkhowa, Facundo Cutuli, James E. Springate and Mary Taub., America Journal of Physiology Renal, 2010, 298, F1222-F1234
• FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML., Keith W. Pratz, Takashi Sato, Kathleen Murphy, Adam Stine, Trivikram Rajkhowa and Mark Levis., Blood, 2010, 115, 1425-1432
• Evidence for post-transcriptional regulation of Na+,K+-ATPase by prostaglandin E1., Maryanne Borsick, Trivikram Rajkhowa, Mary Taub., Biochemical and Biophysical Research Communications, 2006, 345, 739-745
• Identification of a Prostaglandin-responsive Element in the Na/K ATPase β1 promoter that is regulated by cAMP and Ca2+., Keikantse Matlhagela, Maryann Borsick, Trivikram Rajkhowa and Mary Taub., The Journal of Biological Chemistry, 2005, 280, 334-346
• Regulation of the Na, K-ATPase in MDCK cells by prostaglandin E[1]: a role for calcium as cAMP., Taub Mary, Borsick Maryanne, Geisel Janet, Matlhagela, Keikantse, Rajkhowa Trivikram, Allen Cheryl., Experimental Cell Research, 2004, 299, 1-14
• Clonal analysis of immortalized renal proximal Tubule cells: Na[+]/glucose cotransport system levels are maintained despite a decline in transport function., Taub Mary, Ho Jae Han, Rajkhowa Trivikram, Allen Cheryl, Jun Hong Park., Experimental Cell Research, 2002, 281, 205-212

• Diploma in Bioinformatics, Alison, 11/01/25
• NIDA GCP Certification, NIDA Clinical Trials Network, 07/01/25

• Pharmacodynamic Analysis of the Inhibitory Potency of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial., 55th Ash Annual Meeting and Exposition, New Orleans, LA, 2013
• Crenolanib is a Highly Potent, Selective FLT3 TKI with Activity Against D835 Mutations., 54th Ash Annual Meeting and Exposition, Atlanta, GA, 2012
• The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML., 53rd Ash Annual Meeting and Exposition, San Diego, CA, 2011
• FLT3 Mutant to Wild Type Allelic Ratio and Clinical Status Are Predictive of Response to FLT3 Inhibitors in AML., 51st Ash Annual Meeting and Exposition, New Orleans, LA, 2009
• PIM: An Integral Component of FLT3 Signaling and a Potential Therapeutic Target in Acute Myeloid Leukemia., 51st Ash Annual Meeting and Exposition, New Orleans, LA, 2009
• Chronic Exposure to Dopamine Stimulates Na+K+ATPase Pump in Proximal Tubule Cells., Pediatric Academic Societies Annual Meeting, Philadelphia, PA, 2007
• Regulation of the Na+/K+ ATPase in MDCK and variant MDCK cells., Leon Farhi Symposium, 2005
• The Na+/K+ATPase and the Role of PKC, PKA and other signaling pathways in MDCK., Biochemistry Annual Research Day, Buffalo, NY, 2004
• Assessment of the role of the MAP Kinase and PI3 Kinase pathways in mediating growth factor effects on kidney epithelial cells through expression of a constitutively active MAP Kinase Kinase., Biochemistry Annual Research Day, Buffalo, NY, 2003

• Western Blot Analysis
• Mass Spectrometry
• PIA (Plasma Inhibitory Assay)
• ELISA
• Chemiluminescence
• Cell Surface Biotinylation
• Transient Transfection – promoter analysis using luciferase assay system
• Virus Transduction
• SiRNA mediated Knockdown
• CRISPR/Cas9 Screening
• Cell Growth Studies
• MTT Assays
• Molecular Cloning
• Fluorescence Microscopy
• Tissue Culture
• Biorad Protein Assay
• Bone Marrow Stromal Culture
• Primary Cell Culture (cells isolated from the kidneys of adult New Zealand rabbits)
• G418 Titration
• DNA restriction digest/ gel electrophoresis
• DNA Preps
• PCR
• RT-PCR
• QPCR

• Dr. Mark Levis, Professor, Oncology, SKCC at Johns Hopkins, 1650 Orleans Street, CRB1 Room 2M44, Baltimore, MD, 21231, levisma@jhmi.edu, 410-502-3629
• Dr. Gabriel Ghiaur, Associate Professor, Oncology, SKCC at Johns Hopkins, 1650 Orleans St, CRB1 Room 243, Baltimore, MD, 21231, gghiaur1@jhmi.edu, 410-502-3183
• Dr. Jonathan Webster, Assistant Professor, Oncology, SKCC at Johns Hopkins, 1650 Orleans St, CRB1 Room 245, Baltimore, MD, 21231, jwebst17@jhmi.edu, 410-614-9106

• Phase I trial of maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation For Patients with FLT3-ITD AML., 56th Ash Annual Meeting and Exposition, San Francisco, CA, 2014
• FLT3/ITD AML Blasts In Patients Treated with the FLT3 Inhibitor AC220., 52nd Ash Annual Meeting and Exposition, Orlando, FL, 2010
• Regulation of the Na+/K+ATPase in primary proximal tubule cells., Biochemistry Annual Research Day, Buffalo, NY, 2006
• Regulation of the Na+/K+ATPase in cultured epithelial cells., Biochemistry Annual Research Day, Buffalo, NY, 2005